SymBio Pharmaceuticals Limited (TYO:4582)

Market Cap	7.79B
Revenue (ttm)	2.12B
Net Income (ttm)	-4.38B
Shares Out	48.71M
EPS (ttm)	-94.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	113,300
Average Volume	206,340
Open	160.00
Previous Close	160.00
Day's Range	159.00 - 165.00
52-Week Range	126.00 - 475.00
Beta	0.31
RSI	54.31
Earnings Date	May 8, 2025

About SymBio Pharmaceuticals

SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and sales of pharmaceuticals and related operations to treat cancer, hematology, and viral infectious diseases in Japan and internationally. It offers SyB L-0501, an anti-cancer agent for the treatment of non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, and relapsed/refractory diffuse large B-cell lymphoma; SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid administration under the TREAKISYM name. The com...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 108
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4582

Financial Performance

In 2024, SymBio Pharmaceuticals's revenue was 2.45 billion, a decrease of -56.13% compared to the previous year's 5.59 billion. Losses were -3.83 billion, 95.4% more than in 2023.